Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

In May 2024, Zai Lab announced that the Centre for Drug Evaluation (CDE) accepted the sBLA with priority review designation for VYVGART Hytrulo for CIDP in China. The CDE granted the Breakthrough ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...

China’s medicines regulator has granted the nod for the treatment of people with chronic inflammatory demyelinating ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

The Amsterdam-based firm markets Vyvgart, a prescription medicine indicated for neurological conditions, generalized ...

This is the repository that contains source code for the Nerfies website. If you find Nerfies useful for your work please cite: @article{park2021nerfies author = {Park, Keunhong and Sinha, Utkarsh and ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) will release its earnings data after the market closes on Wednesday, ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...